Castle Biosciences CSTL Asset Acquisition Contingent Consideration Liability Noncurrent
Asset Acquisition Contingent Consideration Liability Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's asset acquisition contingent consideration liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's asset acquisition contingent consideration liability noncurrent?
- Castle Biosciences (CSTL) reported asset acquisition contingent consideration liability noncurrent of $1.5M in Q1 2026.
- What does asset acquisition contingent consideration liability noncurrent mean?
- This represents the portion of contingent consideration liabilities arising from asset acquisitions that is expected to be settled beyond one year from the balance sheet date. It captures long-term financial commitments linked to the successful commercialization or clinical development of acquired assets. Tracking this noncurrent liability helps investors evaluate the long-term financial obligations and potential balance sheet volatility associated with strategic acquisitions.